Omeros announces results from nearly three-year follow-up of patients in phase 2 iga nephropathy trial

Seattle--(business wire)--omeros corporation (nasdaq: omer) today announced results of long-term follow-up from the phase 2 clinical trial evaluating its masp-2 inhibitor narsoplimab in patients with iga nephropathy. treatment with narsoplimab in this trial was associated with an unprecedented median reduction in proteinuria of 64.4 percent. now, long-term follow-up (out to 35 months) of these patients shows a markedly slowed rate of decline of estimated glomerular filtration rate (egfr). using
OMER Ratings Summary
OMER Quant Ranking